Funding for this research was provided by:
National Institutes of Health (NIDDK 1R41DK119052-01, U01-AI24290)
Received: 12 August 2021
Accepted: 1 December 2021
First Online: 10 January 2022
: SJW is the founder of Ridgeline Therapeutics, HN is a paid employee of Ridgeline Therapeutics and, since manuscript submission, ADW has also become a paid employee of Ridgeline Therapeutics. The other authors declare no competing interests.